Full-Time

Specialist IS Engineer

Posted on 4/15/2025

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

No salary listed

Mid, Senior

Hyderabad, Telangana, India

Category
Full-Stack Engineering
Software Engineering
Required Skills
LLM
Power BI
Python
JavaScript
SQL
Machine Learning
Tableau
Databricks
Requirements
  • Master’s degree with 4 to 6 years of experience in Computer Science, software development or related field
  • Bachelor’s degree with 6 to 8 years of experience in Computer Science, software development or related field
  • Diploma with 10 to 12 years of experience in Computer Science, software development or related field
  • Hands-on Expertise in database programming languages, data modelling concepts, using SQL and Databricks
  • Experienced in one or more general programming languages, including but not limited to: Python or JavaScript
  • Experienced with reporting tools such as Power BI, Tableau
  • Working knowledge of PV terminologies and Regulatory compliance
  • Excellent problem-solving skills and a commitment to resolving challenges
  • Extensive experience with SDLC
  • Collaborative spirit and effective communication skills to seamlessly work in a cross-functional team
  • Experience with Application Programming Interface (API integrations) such as MuleSoft and Extract Transform Load (ETL tools) as Informatica platform, and Databricks
  • An ongoing commitment to learning and staying at the forefront of AI/ML advancements
  • Outstanding ability to explain technical concepts to non-technical clients
  • Knowledge with ITIL process
  • Support technical implementation aspects of projects including planning, architecture, design, development, and testing to follow Information Systems (IS) Change Control and GxP validation process
Responsibilities
  • Design, develop and deploy solutions to support pharmacovigilance systems
  • Develop and maintain solutions to enhance adverse event intake / distribution ensuring consistency and accuracy across systems related to adverse events/product complaints
  • Overall accountability of technical implementation aspects of projects including planning, architecture, design, development, and testing to follow Information Systems Change Control and GxP validation process
  • Work with partners to identify and prioritize system enhancements and new functionalities to meet evolving business needs of safety systems
  • Develop innovative solutions using generative AI technologies including large language models (LLMs) like Open AI GPT for enhanced decision making and drive efficiency
  • Using strong rapid prototyping skills, quickly translate concepts into working code
  • Conduct code reviews to ensure code quality and consistency to standards
  • Create and maintain documentation on software architecture, design, deployment, disaster recovery, and operations
  • Identify and resolve technical challenges effectively
  • Stay informed about industry developments, emerging trends, and standard practices relevant to systems and processes
  • Find opportunities for automation and process improvements within drug-safety ecosystem
  • Collaborate with the delivery and platform teams to ensure that the applications are aligned with approved architectural and development guidelines
  • Maintain knowledge of market trends and developments in web application development frameworks and related and new technologies to provide, recommend, and deliver standard methodology solutions
  • Responsible for supporting technical root cause analysis and work with software vendors to resolve Pharmacovigilance systems related issues
Desired Qualifications
  • 3+ years of experience COTS Pharmacovigilance Platforms (for example Argus) is a plus or other safety database
  • Experienced in managing GxP systems and implementing GxP projects
  • Experienced with Cloud Technology such as AWS, Azure
  • Knowledge of Artificial Intelligence (AI), Robotic Process Automation (RPA), Machine Learning (ML), Natural Language Processing (NLP) and Natural Language Generation (NLG) automation technologies with building business requirements
  • SAFe for Teams certification (preferred)

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care and outcomes by providing effective therapeutic solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen's investment in AI aligns with trends in biotechnology innovation.
  • Institutional investments indicate strong market confidence in Amgen's growth.
  • FTC clearance of the Horizon merger may ease future regulatory hurdles.

What critics are saying

  • Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
  • FTC scrutiny of mergers may complicate Amgen's future growth strategy.
  • Advancements in quantum technologies could pose a competitive threat to Amgen.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline of potential new therapies in development.
  • Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

BioSpace
Sep 19th, 2023
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.